Risk factors and early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs.

Authors

null

Katerina Grechukhina

SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM”, Moscow, Russian Federation

Katerina Grechukhina , Natalia Chebotareva , Tatyana Krasnova , Lyudmila Zhukova

Organizations

SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM”, Moscow, Russian Federation, Lomonosow Moscow State University, Moscow, Russian Federation

Research Funding

Institutional Funding
SBIH A.S. Loginov Moscow clinical scientific center

Background: Anti-angiogenic anticancer drugs that block VEGF can cause kidney damage (Fujii et al., 2019). Among the mechanisms of nephrotoxicity thrombotic microangiopathy (TMA) of renal vessels can be distinguished (Estrada et al., 2019). TMA can be accompanied the development of anemia, excessive schistocytes, as well as increased LDH levels and a low platelet count, which indicated the occurrence of endothelial dysfunction and microangiopathic processes (Hauser et al, 2009). The goal of this study was to assess the risk factors of early nephrotoxicity and the utility of NGAL, KIM-1, HIF-1α and nephrin levels in urine as early biomarkers of nephrotoxicity. Methods: The study included 50 patients who received anti-VEGF drugs (aflibercept, bevacizumab or ramucirumab). Nephrotoxicity was determined as a decrease in glomerular filtration rate (GFR) to < 60 ml/min/1.73m2 at 8 weeks from the initiation of therapy. The laboratory parameters and the levels of KIM-1, NGAL, HIF-1α and nephrin in urine samples were determined by ELISA before treatment and after 1, 2, 4 and 8 weeks of treatment. To assess risk factors for nephrotoxicity we analyzed primary clinical and laboratory parameters. Results: Nephrotoxicity at 8 weeks was achieved in 21 (42%) of patients. A statistically significant decrease in hemoglobin and platelet count by 20 and 26%, respectively, from the initial level was observed. An increase in the number of schistocytes and a slight increase in LDH levels were also observed. The increase in NGAL, KIM-1 and nephrin levels was statistically significant in 1 weeks and the increase of HIF-1α in 2 weeks after the start of therapy (p = 0.001). The unfavorable predictors of nephrotoxicity as well as the favorable predictors in terms of decreasing renal function are presented in Table. ROC analysis demonstrated high sensitivity and specificity: NGAL – AUC 0.7; KIM-1 – AUC 0.69; HIF-1α– 0.7; nephrin – AUC 0.7. Conclusions: We report a significant increase in the parameters of microangiopathic hemolysis and in urine biomarkers of tubular and podocytic damage as well as hypoxia by the 8th week of treatment. We suggest that the TMA process can take part in renal damage. Increased levels of NGAL, KIM-1, HIF-1α and nephrin in the urine reflect the renal damage processes and have higher sensitivity and specificity then serum creatitine. The independent risk factors for nephrotoxicity are determined.

Predictors of early nephrotoxicity of anti-VEGF drugs.
FactorOdds ratio95% confidence intervalP value
Unfavorable predictors
Initial decrease in estimated GFR less than 100 ml/min/1.73m23.251.36-9.970.004
History of arterial hypertension1.501.44-1.990.013
Increase of NGAL, KIM-1 in 1 week and HIF-1α in 2 weeks in urine after the initiation of treatment7.801.30-35.550.010
Favorable predictors
Adequate control of hypertension0.130.04-0.360.001
Normal level of D-dimer during 8 weeks0.310.09-0.800.040

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Late and Long-Term Adverse Effects

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e24079)

DOI

10.1200/JCO.2023.41.16_suppl.e24079

Abstract #

e24079

Abstract Disclosures

Similar Abstracts